《2005 Coronavirus vaccine promising in SARS prevention》由会员分享，可在线阅读，更多相关《2005 Coronavirus vaccine promising in SARS prevention（1页珍藏版）》请在金锄头文库上搜索。
1、Inpharma 1469 - 8 Jan 2005 Sinovacs coronavirus vaccine* induces coronavirus-neutralising antibodies and is a promising development in SARS prevention,*according to preliminary results from a phase I study. In this study, 36 healthy volunteers were randomised to receive two doses of a coronavirus va
2、ccine (n = 24) or placebo, 28 days apart. After the preliminary 56-day observation period, blood serum conversion was observed in 11 of 12 and 12 of 12 subjects who received high and low doses of the vaccine, respectively. The antibody serum conversion rates were 50% and 100% at days 35 and 42, resp
3、ectively. * Sinovac Biotech; phase I for coronavirus infections in China * severe acute respiratory syndrome Sinovac Biotech Ltd. Sinovac Biotech Ltd. Releases Further Results From SARS Vaccine Phase I Human Clinical Trial. Media Release : 13 Dec 2004. Available from: URL: 809042979 1 Inpharma 8 Jan 2005 No. 14691173-8324/10/1469-0001/$14.95 Adis 2010 Springer International Publishing AG. All rights reserved
